Hepion Pharmaceuticals (HEPA)
(Delayed Data from NSDQ)
$0.69 USD
0.00 (0.44%)
Updated Sep 26, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Hepion Pharmaceuticals, Inc. [HEPA]
Reports for Purchase
Showing records 21 - 40 ( 52 total )
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Five Reasons to Meet the Team in June with Phase 2a NASH Data in YE20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Competing in the NASH dash -Initiation of coverage
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Three Must Dial-In Calls Next Week:
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Three Must Dial-In Calls Next Week: NASH, Omega-3s, and COVID-19 - MS
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dial in Today to Part 1 of Our 4-Part NASH COVID-19 Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Miss Part 1 on Monday of Our 4-Part NASH COVID-19 Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dial in to Part 2 of Our COVID-19 Drug Developer Call Series Today at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Dial in to Part 1 of Our COVID-19 Drug Developer Call Series Today at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Dial in to Parts 1-2 of Our COVID-19 Drug Developer Series on Apr. 1 - Apr. 2
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Meet Our COVID-19 Drug Developers Call Series
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Coronavirus Note, Vol. 5: COVID-19 in Co-Morbidities, Chloroquine, and More
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NASH/CVD/Renal Companies to See and Why at Our 32nd Conference?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Forget to Dial-in to Our NASH Call Today with Dr. Arun Sanyal at 1PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Our NASH Expert Call with Dr. Arun Sanyal Moved to Friday, Feb. 21, at 1PM ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Forget to Dial-in to Our Call Today with Dr. Arun Sanyal at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Can''t Miss Takeaways from our NASH Fibrosis Expert Call with Dr. Scott Friedman
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y